Prodrugs: Some thoughts and current issues

Journal of Pharmaceutical Sciences

Volumn 99, Issue 12, 2010, Pages 4755-4765

  Stella, Valentino J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Drug delivery; Historical perspective; Issues; Prodrugs

Indexed keywords

4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; APAZIQUONE; BRIVANIB ALANINATE; CEFTAROLINE FOSAMIL; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; ESLICARBAZEPINE ACETATE; GABAPENTIN ENACARBIL; GW 695634; PRODRUG; ROMIDEPSIN; THREO 3,4 DIHYDROXYPHENYLSERINE;

ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HUMAN; PATENT;

EID: 78049512700     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22205     Document Type: Article

References (21)

1. Stella V, Higuchi T, Hussain A, Truelove J. 1975. The chemistry of a novel 5, 5-diphenylhydantoin pro-drug. In: Higuchi T, Stella V, editors. Pro-drugs as novel drug delivery systems. Washington, DC: American Chemical Society. pp. 154-183.
2. Higuchi T, Stella VJ. 1974. Esters of hydantoic acid. U.S. Patent #3, 792, 081 (February 12).
3. Glazko AJ, Dill WA, Wheelock RH, Young RM, Nemanich A, Croskey L, Stella V, Higuchi T. 1975. The metabolic disposition of a novel 5, 5-diphenylhydantoin pro-drug. In: Higuchi T, Stella V, editors. Pro-drugs as novel drug delivery systems. Washington, DC: American Chemical Society. pp. 184-195.
4. Varia SA, Stella VJ. 1984. Phenytoin prodrugs VI; In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. J Pharm Sci 73: 1087-1090.
5. Stella VJ. 1996. A Case for prodrugs, fosphenytoin. Adv Drug Deliv Rev 19: 311-330.
6. Stella VJ. 2004. Prodrugs as therapeutics. Expert Opin 14: 277-280.
7. Gaudilliere B, Bernardeli P, Berna P. 2001. To market, to market-2000. Ann Rep Med Chem 36: 293-329.
8. Bernardeli P, Gaudilliere B, Vergne F. 2002. To market, to market-2001. Ann Rep Med Chem 37: 257-277.
9. Boyer-Joubert C, Lorthios E, Moreau F. 2003. To market, to market-2002. Ann Rep Med Chem 38: 347-374.
10. Hegde S, Carter J. 2004. To market, to market-2003. Ann Rep Med Chem 39: 337-368.
11. Hegde S, Schmidt MJ. 2005. To market, to market-2004. Ann Rep Med Chem 40: 443-473.
12. Hegde S, Schmidt MJ. 2006. To market, to market-2005. Ann Rep Med Chem 41: 439-477.
13. Hegde S, Schmidt MJ. 2007. To market, to market-2006. Ann Rep Med Chem 42: 505-554.
14. Hegde S, Schmidt MJ. 2008. To market, to market-2007. Ann Rep Med Chem 43: 455-497.
15. Hegde S, Schmidt MJ. 2009. To market, to market-2008. Ann Rep Med Chem 44: 577-632.
16. Stella VJ, Borchardt RT, Hageman M, Oliyai R, Maag H, Tilley J, editors. 2007. Prodrugs: Challenges and rewards, Vol. 5 in the "Biotechnology: Pharmaceutical Aspects" series. New York, NY: Springer/AAPS Press.
17. Testa B, Mayer JM. 2003. Hydrolysis in drug and prodrug metabolism: Chemistry, biochemistry, and enzymology. Weinheim, Federal Republic of Germany: Wiley-VCH.
18. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, Savolainen J. 2008. Prodrugs: Design and clinical applications. Nat Rev Drug Discov 7: 255-270.
19. See for details of the FDA response.
20. See for details.
21. Murdock KC, Lee VJ, Citarella RV, Durr FE, Nicolau G, Kohlbrenner M. 1993. N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity. J Med Chem 36: 2098-2101.